Tulmimetostat DL2 QD

Preclinical

Tulmimetostat DL2 QD is one of 2 therapeutic programs targeting Castrate Resistant Prostate Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Castrate Resistant Prostate CancerRecruiting

Castrate Resistant Prostate CancerPreclinical

Recruiting

Competition

Competitive Landscape

8 competitors in Castrate Resistant Prostate Cancer

#DrugCompanyPhaseTrials

JSB462

Novartis

Preclinical

1 2

Tulmimetostat DL2 QD

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

PreclinicalRecruiting

Castrate Resistant Prostate Cancer

NCT07206056

Clinical

Trials by Indication[1]

Castrate Resistant Prostate Cancer1 trial

TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Recruiting· Novartis logo

Novartis·Preclinical·NCT07206056·188 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tulmimetostat DL2 QD. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tulmimetostat DL2 QD. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Novartis

Tulmimetostat DL2 QD

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Castrate Resistant Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News